Combogesic

Quick links to important sections

Combogesic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Combogesic

Property Description
Active ingredient Ibuprofen and Paracetamol (Acetaminophen)
Form Film-coated tablet, Solution for infusion
Pharmacological class Analgesic combination (NSAID + Analgesic/Antipyretic)
Common use Pain relief and fever reduction
Origin Synthetic

What Type of Medicine is Combogesic?

Combogesic is a Fixed-Dose Combination (FDC) medicine classified as an analgesic combination intended for the general relief of pain and fever. This synthetic product simultaneously delivers two distinct active compounds, Ibuprofen and Paracetamol (Acetaminophen), in a single formulation. The medicine is structurally designed to achieve an enhanced pain relief outcome compared to single-ingredient treatments. The regulatory filing for the intravenous form of this combination confirmed its use for the management of acute pain. Combogesic is primarily positioned for use in adults who require stronger relief than can be achieved with an over-the-counter (OTC) monotherapy.


What is the Composition of Combogesic?

The active composition of Combogesic consists of Ibuprofen and Paracetamol. This specific pairing unites the properties of a Nonsteroidal Anti-inflammatory Drug (NSAID) with those of a primary analgesic and antipyretic agent. The strategic inclusion of both active compounds in the FDC format facilitates a dual mechanism of action, targeting both the central perception and the peripheral generation of pain signals, such as those caused by inflammation. The product's effectiveness as a combination therapy is clinically recognized for providing superior analgesia when compared to the individual components alone. The primary pharmaceutical preparations are the film-coated tablet for oral intake and the sterile solution for infusion for intravenous administration.


Why Use an Ibuprofen and Paracetamol Combination?

The primary rationale for using the combined formulation is to achieve a synergistic effect in the management of acute pain. By leveraging the unique, distinct pain relief pathways of both Ibuprofen and Paracetamol simultaneously, the product is engineered to offer a more robust analgesic and antipyretic outcome than a single-ingredient (monocomponent) treatment. This comprehensive strategy delivers relief for general discomfort, such as muscle aches or headaches, addressing pain both at the site of irritation and within the central nervous system, making it suitable for effective short-term use.

What side effects are possible with Combogesic?

Possible side effects and safety information

The safety profile for the fixed-dose combination of Ibuprofen and Paracetamol is based on the risks associated with its two active components, as documented in official government regulatory sources.

Adverse reactions are classified by frequency, with Common effects generally involving the gastrointestinal system and nervous system. These frequently listed effects include nausea, vomiting, dyspepsia (indigestion), headache, and dizziness. Uncommon effects may involve the skin, such as rashes or pruritus, and Rare effects include disorders of the blood and lymphatic system (e.g., thrombocytopenia).

Serious Adverse Reactions

Regulatory documents highlight the potential for several serious reactions, reflecting the safety characteristics of the individual components:

  • Gastrointestinal Risk: Potential for serious events such as ulceration, perforation, or bleeding, which are associated with the Ibuprofen component.
  • Hepatotoxicity: Risk of severe liver damage or failure associated with the Paracetamol component.
  • Cardiovascular Risk: Increased risk of serious thrombotic events, including myocardial infarction (heart attack) and stroke, associated with the NSAID (Ibuprofen) component.

Population and Duration Safety Notes

Specific safety considerations are noted in official labeling for certain groups. Older adults are at a higher risk for serious gastrointestinal adverse events. Furthermore, the combination is generally restricted for use in individuals with severe hepatic impairment or severe renal impairment.

The official labeling notes that the risk for serious gastrointestinal and cardiovascular complications may be dose-related and increase with longer duration of use.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose profile for this Ibuprofen and Paracetamol combination product is defined by the toxicological risks associated with both active components. Immediate medical attention and contact with emergency services immediately are required upon known or suspected overdose. Urgent admission to a hospital is necessary for observation and management, even in the absence of obvious symptoms initially, due to the risk of delayed, severe toxicity from the Paracetamol component.

Documented Overdose Manifestations

System Official Signs and Symptoms
Gastrointestinal Nausea, Vomiting, Abdominal pain, Diarrhoea, Anorexia.
CNS Dizziness, Headache, Tinnitus, Lethargy, Drowsiness.
Late Signs Jaundice (indicating hepatotoxicity).

Severe Outcomes and Management

Overdose can lead to life-threatening outcomes, including hepatic failure (Paracetamol risk) and acute renal failure (Ibuprofen risk). Severe metabolic acidosis, coagulation defects, hypotension, and coma are also documented. Symptomatic and supportive treatment is the primary management approach. N-acetylcysteine (NAC) is the specific intervention used for Paracetamol toxicity, while no specific antidote is known for Ibuprofen overdose.

Therapeutic Uses of Combogesic

What Combogesic Treats: Main Uses and Benefits

The Ibuprofen and Paracetamol combination is an analgesic applied in situations involving certain distressing symptoms associated with acute conditions. It is relevant when short-term symptomatic assistance is needed.

This fixed-dose combination is used for the short-term symptomatic management of mild to moderate pain in adults.

This medication is commonly used to help with symptoms related to physical discomfort, addressing conditions such as headache, muscular aches, dental pain, backache, and symptomatic relief during menstrual cramps. It provides supportive relief when symptoms interfere with daily comfort, offering symptomatic relief that helps patients cope more steadily with difficult episodes of pain and can assist in easing symptoms related to inflammatory or irritative states and fever.

It is also applicable within clinical settings that involve acute or disruptive symptom patterns, and is often used during phases when symptoms become more noticeable, such as after dental procedures or in postoperative recovery. This supportive therapeutic approach may assist with maintaining functional stability by providing short-term symptomatic assistance when functional stability becomes affected.


Quick Fact: Relief for Inflammation and Pain The treatment is commonly used across conditions presenting with acute episodes where both analgesic and anti-inflammatory support is needed.

Eligibility and Restrictions for Use

Official regulatory documents establish strict criteria for who can and cannot use Combogesic (acetaminophen and ibuprofen combination). The medication is indicated for use in adults (age 18 and older), meaning it is contraindicated in children and adolescents.

Eligibility Restrictions

Classification Restricted Population Contextual Constraint
Contraindicated Patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or any component of the formulation. Includes patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
Contraindicated Patients with severe hepatic impairment, severe renal failure, or severe heart failure (NYHA Class IV). Also prohibited in cases of active gastrointestinal bleeding or peptic ulceration (active or recurrent history).
Contraindicated Patients undergoing coronary artery bypass graft (CABG) surgery (for peri-operative pain). Prohibited during the third trimester of pregnancy (after 30 weeks gestation).
Not Recommended Patients with hepatic or renal impairment (non-severe). Caution is advised for the elderly and for women planning a pregnancy or during the first 6 months of pregnancy.

Use is not recommended in patients with pre-existing conditions like severe heart failure (NYHA Class II-III), or uncontrolled hypertension unless the benefits are determined to outweigh the risk.

What should I know about interactions with other medicines?

Combogesic is a fixed-dose combination of acetaminophen and ibuprofen, and its interaction profile is derived from the known risks of each component. The most critical interaction-related instruction is the absolute restriction against co-administering this product with any other medicine containing acetaminophen or NSAIDs (Nonsteroidal Anti-inflammatory Drugs), including over-the-counter ibuprofen, aspirin, or selective COX-2 inhibitors. Using multiple acetaminophen-containing products significantly increases the risk of severe liver damage, while combining NSAIDs raises the risk of gastrointestinal bleeding and ulceration.

The ibuprofen component interacts with several classes of prescription medicines. Concomitant use with anticoagulants (such as warfarin) and antiplatelet agents (including low-dose aspirin) increases the risk of serious bleeding events. Furthermore, the combination should be used with caution alongside antihypertensives (ACE inhibitors, ARBs, Beta-Blockers) and diuretics, as NSAIDs can reduce their effectiveness and increase the risk of kidney impairment, particularly in the elderly. Monitoring is also necessary when used with Lithium or Methotrexate, as ibuprofen can elevate their concentrations, increasing the potential for toxicity.

Mechanism of Action

The function of this medicine is based on a dual-action mechanistic strategy that targets the chemical origin and the central perception of nociceptive signals simultaneously.

Modulating Peripheral Pain Generation

This mechanism is primarily driven by the Ibuprofen component, which acts as an inhibitor of the Cyclooxygenase (COX) enzymes in peripheral tissues. By blocking these enzymes, the drug restricts the synthesis of prostaglandins , which are key chemical mediators that sensitize peripheral pain-sensing nerves. This molecular action diminishes the peripheral sensitization of nociceptors, resulting in a peripheral antinociceptive and anti-inflammatory physiological effect.


Targeting Central Perception and Thermoregulation

The Paracetamol component exerts its influence mainly within the Central Nervous System (CNS), modulating central pain pathways and temperature control. This involves complex interactions, including the reduction of prostaglandin synthesis in the hypothalamus (the brain's thermal center) and possible modulation of the CB1 Cannabinoid Receptor via a metabolite. This central mechanism dampens the brain's processing of incoming nociceptive input and results in the resetting of the elevated thermal set-point, contributing to antipyresis and central antinociception.


Synergistic Dual-Action Mechanism

The combination utilizes the complementary nature of these two distinct domains—peripheral inhibition and central modulation. By addressing both the source of the chemical signaling in the body (Ibuprofen) and the central interpretation of those signals (Paracetamol), the drug engages mechanisms that influence both signal generation and perception. This coordinated physiological effect targets both peripheral signaling and central perception, producing a broad spectrum of modulated activity across both mechanistic domains.

Dosage and Administration Information

How Combogesic is Used: Official Administration Guidelines

This medicine, a fixed-dose combination of Ibuprofen and Paracetamol (Acetaminophen), is administered according to strict instructions. The primary methods of delivery are the oral route via a film-coated tablet and the intravenous (IV) infusion via a ready-to-use solution, depending on the patient's clinical needs.

Dosing Schedule and Frequency

The standard pattern for both forms is as-needed use, with a required interval of 6 hours between administrations. Single doses vary based on the form and regional label. The oral tablet strength most commonly prescribed contains 500 mg Paracetamol and 150 mg Ibuprofen. For the IV solution, a 100 mL vial, containing 1000 mg Paracetamol and 300 mg Ibuprofen, is administered to adults weighing over 50 kg.

The maximum recommended daily dose must not exceed a combined total of 4000 mg Paracetamol and 1200 mg Ibuprofen within a 24-hour period. Use is uniformly restricted to short-term management; the duration is limited to a maximum of 3 days for the oral tablet and 2 days for the intravenous solution.

Administration Conditions

For the intravenous form, administration must be performed as a slow 15-minute infusion. The IV route is reserved only for situations where it is considered necessary and the oral route is not feasible. The product is not recommended for use in individuals under 18 years of age. Patients with renal or hepatic impairment may require a reduced initial dose, as specified in the official prescribing information.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Overview of Active Ingredient Research

Research has explored the ingredient's potential role in the body. Studies have investigated the ingredient's role in managing pain symptoms. This fixed-dose combination contains two established analgesics, paracetamol (acetaminophen) and ibuprofen, which are thought to act on different pain pathways.

  • Primary Studies: Initial laboratory and animal studies examined the anti-inflammatory properties of the ibuprofen component and the central analgesic effects of paracetamol.
  • Human Trials: Subsequent Phase 3 clinical trials, including randomized controlled trials (RCTs) following procedures like dental or orthopedic surgery, evaluated the combination's short-term role in relation to acute pain symptoms.

Combination Therapy Findings

Studies have reported the rates of adverse events observed in groups receiving this combination in adults. The safety profile has generally been described as comparable to that of the individual components when used alone.

Research has compared the combination to single-drug treatments and examined whether there is a long-term change in symptoms. It is not yet clear whether the long-term profile differs significantly from those studied. Research has described the scope of investigation regarding the ingredient's role in mild to moderate acute pain.

Specific Findings on Symptom Markers

One large RCT reported a change in an inflammation marker in the group receiving the drug. The study examined the ingredient's association with blood markers of inflammation over a four-week period. Many studies have focused on the combination's ability to reduce the need for opioid rescue medication post-surgery.

  • Dose-Response: Other trials investigated different dosages, but the evidence remains limited regarding which dose may be associated with the most favorable outcomes for all patients.

The evidence base is being developed. Studies have explored potential outcomes for users. Further research is required to clarify the full long-term profile.

Frequently Asked Questions (FAQ)

Common questions about Combogesic (FAQ)


Q: How is Combogesic different from taking ibuprofen and paracetamol separately?

A: Official product information describes this medicine as a Fixed-Dose Combination that delivers both Ibuprofen and Paracetamol in a single tablet. This combination is intended to create a synergistic effect, meaning the two ingredients work together to provide pain relief by combining Ibuprofen's peripheral, anti-inflammatory action with Paracetamol's central pain relief pathway.


Q: Can Combogesic be used for headaches or migraines?

A: The medicine is officially indicated for the short-term management of mild to moderate acute pain. Official patient resources sometimes list headache, toothache, and menstrual cramps as types of general pain that the medicine is used for.


Q: Does alcohol interact with Combogesic?

A: Regulatory documents explicitly advise patients to avoid consuming alcohol while taking this medicine. Regular or heavy alcohol use may increase the risk of serious side effects, particularly the risk of liver injury, which is associated with the Paracetamol component.


Q: What is the difference between NSAIDs and simple analgesics like paracetamol?

A: Ibuprofen is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), which primarily works by reducing inflammation at the site of injury. In contrast, Paracetamol (Acetaminophen) is categorized as a simple analgesic and antipyretic agent, which focuses on relieving pain and reducing fever, mainly within the central nervous system.


Q: Does Combogesic affect the ability to drive or operate machinery?

A: Official regulatory labeling states that side effects that affect the nervous system, such as dizziness and sleepiness, are possible. If these effects are experienced, it is recommended to avoid driving or operating complex machinery, as judgment may be impaired.


Q: Can I take Combogesic if I have a history of asthma?

A: According to the official prescribing information, the medicine is contraindicated (prohibited) for use in patients who have a history of asthma, hives (urticaria), or allergic-type reactions after taking aspirin or other NSAIDs.


Q: Can Combogesic be taken on an empty stomach?

A: Official administration instructions generally advise taking the tablets with a full glass of water. While it may be taken without food, one official warning suggests taking it with food or milk if an upset stomach occurs.


Q: Does Combogesic contain lactose or other common excipients?

A: Yes, the film-coated tablet formulation is listed in official documents as containing specific non-medicinal ingredients (excipients), including lactose monohydrate in the coating. Patients with known intolerances to excipients, such as lactose, should consult the complete list.


Q: Can Combogesic be used by people with heart conditions?

A: The official labeling provides restrictions for heart conditions. It is contraindicated for patients with severe heart failure (NYHA Class IV) and is generally not recommended for those with moderate heart failure or uncontrolled high blood pressure, unless the benefits are determined to outweigh the risk, as outlined in the prescribing information.


Q: Does Combogesic cause changes in mood or anxiety?

A: Adverse events reported in official documents involve the nervous system, with effects like headache and dizziness being common. Adverse events listed in the official documentation may include less frequent effects on the nervous system, such as abnormal dreams or hallucinations.


Q: Do you need a prescription for Combogesic?

A: The legal status of the medicine, which dictates if a prescription is required, varies by country and by formulation. In some regions, the oral tablet is available by prescription only or behind the counter, while the intravenous (IV) solution is restricted to hospital use.


Q: Is Combogesic known by other names in different countries?

A: Yes, the fixed-dose combination of acetaminophen and ibuprofen is marketed under different brand names in various regions, depending on the regulatory authorization. Examples of similar combination products include Maxigesic and Advil Dual Action with Acetaminophen.


Q: Are there any signs that Combogesic might not be working for someone?

A: Official patient information instructs users to contact a healthcare provider if pain or fever does not respond to a specific dose within the recommended limits. If the expected relief is not achieved after following the administration guidelines, this is a reason to seek further guidance.


Q: What happens if I miss a scheduled dose of Combogesic?

A: Official guidelines describe that a missed dose is typically taken as soon as it is remembered. However, if it is near the time of the next scheduled dose, the regulatory instruction is to skip the missed dose and resume the normal dosing schedule. Users are cautioned not to take a double dose.


Q: Is it possible to become dependent on Combogesic?

A: The active ingredients are Ibuprofen and Paracetamol, neither of which are classified as controlled substances. The official regulatory labeling for the medicine does not include warnings about addiction or the potential for physical dependence.


Q: Can I take Combogesic while taking common allergy medications?

A: Official documentation lists specific prescription drug interactions, but for over-the-counter allergy medicines, the importance of informing a healthcare provider about all medicines being taken is highlighted in official documentation, as interactions between various non-prescription products are always possible.


Q: What food or drink should be avoided when taking Combogesic?

A: The most notable substance requiring avoidance is alcohol, due to the increased risk of liver damage associated with the Paracetamol component. There are no other specific foods or drinks explicitly prohibited in the official regulatory documentation.


Q: Are there any known interactions between Combogesic and herbal supplements?

A: Official patient information highlights the need to disclose all products, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements, to a healthcare provider. This disclosure is necessary because interactions are possible with many non-pharmaceutical products.


Q: Do official sources mention any long-term effects of the combination drug?

A: Regulatory documents restrict the medicine's use to short-term management only. They also note that the risk for serious gastrointestinal and cardiovascular complications may increase with a longer duration of use, and official research summaries indicate that further research is required to clarify the full long-term profile.


Q: Is Combogesic suitable for minor aches and pains?

A: The medicine is officially indicated for the short-term management of mild to moderate acute pain. Patient-facing resources often describe its use for general discomfort, including common symptoms like muscle aches and minor aches and pains.


Q: Is there a generic version of Combogesic available?

A: Generic versions of the Ibuprofen/Acetaminophen combination are available in some countries. However, the availability of a specific generic version depends on regional regulatory approvals and the expiration of patents for both the oral and intravenous forms of the combination product.


Q: What populations were excluded from the main clinical trials of Combogesic?

A: The full list of populations excluded from clinical trials is complex, but the regulatory labeling provides key exclusion criteria. Examples include patients with severe hepatic impairment (liver damage), a history of severe allergic reactions to NSAIDs, or those undergoing Coronary Artery Bypass Graft (CABG) surgery.

How should Combogesic be stored and disposed of?

How to Store and Dispose of Combogesic

Combogesic tablets require storage at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with storage limits permitting temperatures up to 30 C.

Storage Requirements

  • Temperature: Store below 30 C at controlled room temperature.
  • Protection: The medicine must be kept in the original package (blister) to protect it from light.
  • Child Safety: Government labeling strictly mandates storing the product out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Any unused or expired Combogesic must be disposed of in accordance with local regulations. This often involves using a drug take-back program or following specific governmental procedures for household trash disposal. Medicines should not be disposed of via wastewater or household garbage unless officially instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Combogesic found in:

A-Z Index: